Semaglutide vs Retatrutide
The two ends of the incretin design space: a selective GLP-1 analog against a triple agonist.
Metabolic
Semaglutide
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
Metabolic
Retatrutide
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
Side by side
| Dimension | Semaglutide | Retatrutide |
|---|---|---|
| Molecular weight | 4113.58 g/mol | 4731.32 g/mol |
| Size class | long peptide | long peptide |
| CAS number | 910463-68-2 | 2381089-83-2 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg, 10mg, 20mg | 10mg, 20mg, 30mg |
| Entry price | $44 | $99 |
| Cost per mg | $6.45 | $7.47 |
Mechanism
Semaglutide
Semaglutide is a 31-amino-acid GLP-1 analog structurally modified at position 8 (Aib substitution) to resist DPP-4 degradation, with a C18 fatty diacid chain conjugated via a spacer at Lys26 that promotes albumin binding. These modifications extend its half-life substantially relative to native GLP-1, which has a circulating half-life measured in minutes. It is among the most heavily published peptides in modern metabolic research.
Retatrutide
Retatrutide is a single-molecule triple agonist acting at the GIP, GLP-1, and glucagon receptors. The inclusion of glucagon receptor agonism is mechanistically distinct from dual agonists: glucagon receptor activation is studied for effects on hepatic lipid handling and energy expenditure, pathways not engaged by incretin agonism alone. It remains investigational and is a frequent subject of comparative receptor-pharmacology work.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
Semaglutide
Evidence base: extensive, independently replicated, with published receptor-level and pharmacokinetic characterization.
Full research reference →Retatrutide
Evidence base: emerging. Receptor pharmacology characterized; long-term and independent replication limited by the compound's investigational status.
Full research reference →Research applications
Semaglutide
- Incretin receptor signaling and β-cell response studies
- Gastric emptying and satiety-pathway research in rodent models
- Comparative pharmacokinetics against dual and triple agonists
- Receptor binding affinity and selectivity assays
Retatrutide
- Triple receptor agonism and pathway-contribution studies
- Hepatic lipid metabolism research in preclinical models
- Energy expenditure and thermogenesis pathway assays
- Head-to-head comparison against dual agonists
Common questions
What is the difference between Semaglutide and Retatrutide?
Semaglutide is long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models. Retatrutide is triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research. They differ in molecular weight (4113.58 vs 4731.32 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, Semaglutide or Retatrutide?
Semaglutide is lower at approximately $6.45 per milligram at its best tier, against $7.47 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can Semaglutide and Retatrutide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should Semaglutide and Retatrutide be stored?
Store lyophilized powder at -20°C protected from light. Reconstituted solution is stable at 2-8°C for up to 30 days. For Retatrutide: Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Which has the stronger evidence base?
Semaglutide — Evidence base: extensive, independently replicated, with published receptor-level and pharmacokinetic characterization. Retatrutide — Evidence base: emerging. Receptor pharmacology characterized; long-term and independent replication limited by the compound's investigational status.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.
Comparison generated from NuVida Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.